Annals of Surgical Oncology最新文献

{"title":"ASO Visual Abstract: Risk Factors for Regrowth After Nonoperative Management for Rectal Cancer.","authors":"Neal Bhutiani, Kentaro Ochiai, Oliver Peacock, Y Nancy You, Brian K Bednarski, Craig Messick, John M Skibber, Michael G White, George J Chang, Tsuyoshi Konishi, Abhineet Uppal","doi":"10.1245/s10434-025-17057-7","DOIUrl":"https://doi.org/10.1245/s10434-025-17057-7","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: ASO Author Reflections: Artificial Intelligence-Augmented Detection of Bladder Tumors.","authors":"Zixing Ye, Yingjie Li, Zhigang Ji","doi":"10.1245/s10434-025-17192-1","DOIUrl":"https://doi.org/10.1245/s10434-025-17192-1","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Hopes for Retroperitoneal-First Laparoscopic Approach-Assisted Lymph Node Dissection for Incidental Gallbladder Cancer.","authors":"Takuma Karasuyama, Gozo Kiguchi, Osamu Takeyama","doi":"10.1245/s10434-025-17261-5","DOIUrl":"https://doi.org/10.1245/s10434-025-17261-5","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Anastomotic Leaks on Long-Term Survival in Patients with Esophageal Squamous Cell Carcinoma Following McKeown Esophagectomy: A Propensity Score-Matched Analysis.","authors":"Chufeng Zeng, Xu Zhang, Bei Jia, Yi Hu, Peng Lin, Jianhua Fu, Hao Long, Tiehua Rong, Xiaodong Su","doi":"10.1245/s10434-025-17206-y","DOIUrl":"https://doi.org/10.1245/s10434-025-17206-y","url":null,"abstract":"<p><strong>Background: </strong>The impact of anastomotic leak (AL) on the long-term survival of patients with esophageal squamous cell carcinoma (ESCC) remains unclear. This study investigated whether AL influences the long-term survival of patients with ESCC following McKeown esophagectomy.</p><p><strong>Patients and methods: </strong>An original database was queried to identify patients with ESCC who underwent McKeown esophagectomy between 2012 and 2020 at a high-volume cancer center. Overall survival (OS) and disease-free survival (DFS) were compared using Kaplan-Meier (KM) curves. Cox regression analysis was used for multivariate analysis. Propensity score matching (PSM) was used to adjust for the confounding factors.</p><p><strong>Results: </strong>A total of 1614 patients were included, of whom 16.9% developed AL. In patients without neoadjuvant therapy, for patients with and without AL, the 5-year OS was 55.8% and 62.0%, and the 5-year DFS was 48.7% and 59.1%, respectively (OS: p = 0.37, DFS: p = 0.046). In the neoadjuvant cohort, for patients with and without AL, the 5-year OS was 57.9% and 63.2%, and the 5-year DFS was 55.4% and 58.8%, respectively (OS: p = 0.48, DFS: p = 0.78). Moreover, AL significantly increased the risk of distant recurrence in patients without neoadjuvant therapy (p = 0.023).</p><p><strong>Conclusions: </strong>These findings suggest that AL negatively influences DFS in patients without neoadjuvant therapy, but does not significantly affect long-term survival in patients receiving neoadjuvant treatment. Intensive treatment and follow-up plan should be considered when patients without neoadjuvant therapy.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conditional Relative Survival of Gallbladder Cancer: A Population-Based Study in a High-Incidence Asian Country from 1999 to 2021.","authors":"Mee Joo Kang, Johyun Ha, Sang-Jae Park, Hyeong Min Park, Kyu-Won Jung, Sung-Sik Han","doi":"10.1245/s10434-025-17237-5","DOIUrl":"https://doi.org/10.1245/s10434-025-17237-5","url":null,"abstract":"<p><strong>Background: </strong>Dynamic prognostic information is important for treatment decisions and consultations among patients with gallbladder cancer (GBC), given its poor prognosis, especially in the advanced stage. We aimed to investigate long-term conditional relative survival (CS) rates in patients with GBC in Korea, which has a notably high incidence of GBC.</p><p><strong>Methods: </strong>Data regarding 40,774 individuals diagnosed with GBC between 1999 and 2021 were obtained from the Korea Central Cancer Registry. CS was analyzed across strata, including stage as well as the first course of treatment.</p><p><strong>Results: </strong>The overall 5-year relative survival rate at diagnosis, 3-year CS of 2-year survivors (the probability of surviving another 3 years among 2-year survivors), and 5-year CS of 5-year survivors were 29.9, 79.3, and 91.1%, respectively. Postoperatively, 94.4% (localized stage) and 76.5% (regional stage) of 2-year survivors survived for an additional 3 years. Moreover, 95.4% (localized stage) and 89.4% (regional stage) of 5-year survivors survived for an additional 5 years. The conditional probability of death within the first year after diagnosis increased gradually across age groups among overall patients, with the lowest (33.8%) and highest (67.7%) probabilities being in the 20-39 and ≥ 80 years age groups, respectively.</p><p><strong>Conclusions: </strong>Greater than 75% of patients with regional-stage GBC who survive the initial 2 postoperative years survive for an additional 3 years. Unlike patients with regional-stage GBC, whose 5-year survival rates continue to decrease among 5-year survivors, patients with localized-stage GBC may not require follow-up beyond 5 postoperative years since their survival probability after 5 years exceeds 95%.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.","authors":"Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, Junsung Choi, David J Eschelman, Evan S Glazer, Aslam Ejaz, J Harrison Howard, Erika Richtig, Sebastian Ochsenreither, Sunil A Reddy, Michael C Lowe, Georgia M Beasley, Anja Gesierich, Armin Bender, Martin Gschnell, Reinhard Dummer, Michel Rivoire, Ana Arance, Stephen William Fenwick, Joseph J Sacco, Sebastian Haferkamp, Carsten Weishaupt, Johnny John, Matthew Wheater, Christian H Ottensmeier","doi":"10.1245/s10434-025-17231-x","DOIUrl":"https://doi.org/10.1245/s10434-025-17231-x","url":null,"abstract":"<p><strong>Background: </strong>Metastatic uveal melanoma (mUM) has a poor prognosis, with liver metastases typically presenting a therapeutic challenge. Melphalan/Hepatic Delivery System (Melphalan/HDS) is a drug/medical device combination used for liver-directed treatment of unresectable mUM patients. This study assessed efficacy and safety of Melphalan/HDS versus best alternative care (BAC).</p><p><strong>Methods: </strong>Eligible patients with unresectable mUM were randomized (1:1) to receive Melphalan/HDS (3 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of 6 cycles or BAC. Due to slow enrollment and patient reluctance to receive BAC treatment, the study design was amended to a single-arm Melphalan/HDS study, and all efficacy analyses of the randomized study were treated as exploratory.</p><p><strong>Results: </strong>The study enrolled 85 patients. Eligible patients were randomized to receive Melphalan/HDS (n = 43) or BAC (n = 42), and 72 patients received study treatment (Melphalan/HDS [n = 40]; BAC [n = 32]). Exploratory analyses of efficacy endpoints showed numerical differences consistently favoring the Melphalan/HDS arm versus BAC (median overall survival: 18.5 vs. 14.5 months; median progression-free survival: 9.1 vs. 3.3 months; objective response rate: 27.5% vs. 9.4%; and disease control rate: 80.0% vs. 46.9%). Serious adverse events (SAEs) occurred in 51.2% of Melphalan/HDS and in 21.9% of BAC patients. The most common (>5%) SAEs included thrombocytopenia (19.5%), neutropenia (9.8%), leukopenia (9.8%) and febrile neutropenia (7.3%) in Melphalan/HDS patients and cholecystitis, nausea and vomiting (6.3% each) in BAC patients. No treatment-related deaths were observed.</p><p><strong>Conclusion: </strong>Treatment with Melphalan/HDS shows clinically meaningful efficacy and demonstrates a favorable benefit-risk profile in patients with unresectable mUM as compared to BAC.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Visual Abstract: The Effectiveness of Superparamagnetic Iron Oxide Nanoparticles in Reducing Unnecessary Sentinel Lymph Node Biopsies.","authors":"Erin Kim, Lesly A Dossett, Tasha M Hughes, Jacqueline S Jeruss, Michael S Sabel, Melissa L Pilewskie","doi":"10.1245/s10434-025-17220-0","DOIUrl":"https://doi.org/10.1245/s10434-025-17220-0","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer.","authors":"Adrian Kohut, Matthew L Anderson, Vaagn Andikyan, Maya Yasukawa, Lindsey Nguy, Andreas Karachristos, Timothy Nywening, Gil Mor, Radhika Gogoi, Joshua G Cohen, Jeff F Lin, Thomas J Rutherford","doi":"10.1245/s10434-025-17269-x","DOIUrl":"https://doi.org/10.1245/s10434-025-17269-x","url":null,"abstract":"<p><strong>Background: </strong>Hyperthermic intraperitoneal chemotherapy (HIPEC) is used to eliminate minimal residual disease in patients with peritoneal surface malignancies, including advanced epithelial ovarian cancer (EOC). While some trials suggest potential benefits, the role of HIPEC during cytoreductive surgery (CRS) in EOC remains uncertain. This study aimed to evaluate outcomes for patients undergoing HIPEC during CRS for advanced-stage EOC in the United States (US).</p><p><strong>Methods: </strong>This multicenter, retrospective cohort study included women with stage III-IV EOC who underwent CRS with or without HIPEC between 2006 and 2021 at Commission on Cancer-accredited US facilities. Propensity score matching was used to create a control group of patients who underwent CRS only. Overall survival (OS) was analyzed using the Kaplan-Meier log-rank method and adjusted for confounding factors with Cox proportional hazards regression.</p><p><strong>Results: </strong>Among 1400 patients identified, 700 underwent CRS with HIPEC and 700 underwent CRS only. Of these 1400 patients, 932 underwent interval CRS and 468 underwent primary CRS. No significant difference in median OS was observed between the overall CRS+HIPEC and CRS-only groups (57.6 vs. 47.6 months; p = 0.105). However, interval CRS+HIPEC was associated with significantly improved median OS compared with interval CRS-only (57.6 vs. 45.7 months; p = 0.003). After adjustment, HIPEC remained significantly associated with improved survival (hazard ratio 0.77, 95% confidence interval 0.64-0.92; p = 0.004).</p><p><strong>Conclusions: </strong>HIPEC is associated with improved OS in patients undergoing interval CRS for advanced-stage EOC. Further research should explore the selective use of HIPEC during interval CRS.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Transarterial Chemoembolization for Resectable Single Hepatocellular Carcinoma: A Single-Center Cohort Study.","authors":"Sang-Hoon Kim, Ki-Hun Kim, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Woo-Hyoung Kang, Eun-Kyoung Jwa, Byeong-Gon Na, Sung Min Kim, Sung-Gyu Lee","doi":"10.1245/s10434-025-17257-1","DOIUrl":"https://doi.org/10.1245/s10434-025-17257-1","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of preoperative transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) remains unclear. This study aimed to investigate the impact of preoperative TACE for resectable solitary HCC.</p><p><strong>Methods: </strong>This retrospective study included 4899 patients who underwent hepatectomy from 2008 to 2019. Survival outcomes were compared before and after propensity score matching (PSM) based on tumor size (≤ 3, 3-5, and > 5 cm) between the preoperative TACE (n = 378) and upfront surgery groups (n = 4521). Cox regression analysis was utilized to identify predictors of overall survival (OS) and recurrence-free survival (RFS).</p><p><strong>Results: </strong>For HCC ≤ 3 cm, OS was similar between the groups but RFS significantly improved in the preoperative TACE group both before (OS: p = 0.44; RFS: p < 0.001) and after (OS: p = 0.84; RFS: p < 0.001) PSM. For HCC 3-5 cm, both OS and RFS significantly improved in the preoperative TACE group, both before (OS: p = 0.038; RFS: p < 0.001) and after (OS: p = 0.038; RFS: p < 0.001) PSM. For HCC > 5 cm, OS was not significantly different but RFS improved in the preoperative TACE group both before (OS: p = 0.42; RFS: p = 0.002) and after (OS: p = 0.42; RFS: p = 0.004) PSM. Additionally, complete lipiodol uptake was associated with better OS (p = 0.032) and RFS (p = 0.045) in tumors 3-5 cm compared with incomplete lipiodol uptake. Multivariate analysis identified preoperative TACE and complete lipiodol uptake as significant factors in improving RFS.</p><p><strong>Conclusion: </strong>Preoperative TACE, achieved as complete lipiodol uptake as possible, is recommended to prevent postoperative recurrence of resectable solitary HCC, particularly for tumors measuring 3-5 cm, due to the clear survival benefits in both OS and RFS.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statistical Cure After Hepatectomy for Hepatitis B Virus-Associated Hepatocellular Carcinoma: A Risk-Stratification Model.","authors":"Yi-Fan Li, Lan-Qing Yao, Chao Li, Hong Ren, Jin-Bo Gong, Han Wu, Li-Hui Gu, Ying-Jian Liang, Yu-Ze Yang, Kong-Ying Lin, Zi-Qiang Li, Qi-Xuan Zheng, Ting-Hao Chen, Ya-Hao Zhou, Hong Wang, Hong-Wei Guo, Jia-Hao Xu, Zhong Chen, Feng Shen, Ming-Da Wang, Tian Yang","doi":"10.1245/s10434-025-17176-1","DOIUrl":"https://doi.org/10.1245/s10434-025-17176-1","url":null,"abstract":"<p><strong>Background: </strong>Statistical cure, defined as achieving life expectancy comparable with that of disease-free individuals, has not been specifically investigated in hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC), which accounts for more than 50% of the global HCC burden. This study aimed to develop a cure model for HBV-HCC after hepatectomy using matched HBV carriers and the general population as reference groups.</p><p><strong>Methods: </strong>From a Chinese multicenter database, HBV-HCC patients who underwent curative-intent hepatectomy were retrospectively reviewed. Independent prognostic factors were identified through Cox regression. A spline-based cure model was applied using two reference populations: matched Chinese HBV carriers (from Shanghai Center for Disease Control and Prevention) and the general population (from the National Bureau of Statistics).</p><p><strong>Results: </strong>The study analyzed 740 HBV-HCC patients. The following eight independent risk factors were identified: preoperative high viral load (hazard ratio [HR] 1.27), Child-Pugh grade (HR 1.21 and 1.43), multiple tumors (HR 1.70), tumor size greater than 5.0 cm (HR 1.47), macrovascular invasion (HR 3.33), microvascular invasion (HR 1.25), intraoperative blood transfusion (HR 1.21), and postoperative HBV reactivation (HR 1.89). The overall cure probability was 21.2% versus that for HBV carriers and 11.1% versus that for the general population. Risk stratification identified distinct groups relative to HBV carriers. Low risk (64.2%) showed an initial cure rate of 30.3% and achieved a 95% cure probability by 8.6 years, whereas high risk (10.5%) showed negligible cure probability.</p><p><strong>Conclusions: </strong>This first HBV-HCC-specific cure model demonstrated that statistical cure is achievable for a subset of patients after hepatectomy. Risk stratification identifies patients with varying cure probabilities, providing valuable guidance for personalized treatment strategies and surveillance protocols.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}